Corbus Pharmaceuticals Secures FDA Alignment for CRB-701 Registration Path in HNSCC and Cervical Cancer — Corbus Pharmaceuticals Holdings, Inc.

Event summary

FDA aligns with Corbus on registrational study designs for CRB-701 in second-line HNSCC and cervical cancer, with ORR as primary endpoint for accelerated approval.
Dr. Dominic Smethurst to step down as Chief Medical Officer on June 30, 2026.
Updated CRB-701 monotherapy data to be presented at ASCO 2026, including clinical response durability and HNSCC patient subgroup analysis.
Corbus anticipates reporting data with CRB-701 in combination with Keytruda® in first-line HNSCC patients in Q4 2026.

The big picture

Corbus Pharmaceuticals' alignment with the FDA on the registration path for CRB-701 marks a critical transition from clinical proof of concept to late-stage development. The company's focus on addressing unmet medical needs in HNSCC and cervical cancer positions it within the competitive oncology landscape, where targeted therapies and ADCs are increasingly gaining traction. The upcoming data presentations and potential combination studies with Keytruda® will be key indicators of CRB-701's potential to differentiate itself in the market.

What we're watching

Regulatory Strategy: Whether Corbus can successfully finalize protocols and statistical analysis plans for registrational studies with the FDA.
Clinical Data: The impact of updated CRB-701 monotherapy data presented at ASCO 2026 on investor and regulatory confidence.
Leadership Transition: How the departure of Dr. Dominic Smethurst as Chief Medical Officer will affect the company's clinical development pipeline.